TOM-1

Cat.No.: CSC-C0583

Species: Homo sapiens (Human)

Source: Bone Marrow

Morphology: small round cells growing in suspension singly or in clumps, some cells are loosely adherent

Culture Properties: suspension

Inquire for Price

Specification
Background
Scientific Data
Q & A
Customer Review

Cat.No.

CSC-C0583

Description

Established in 1983 from the bone marrow of a 54-year-old woman with refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL); described to carry the ALL-variant (m-bcr) of the BCR-ABL1 fusion gene (e1-a2)

Species

Homo sapiens (Human)

Source

Bone Marrow

Recommended Medium

80% RPMI-1640 + 20% h.i. FBS

Culture Properties

suspension

Morphology

small round cells growing in suspension singly or in clumps, some cells are loosely adherent

Karyotype

Human hyperdiploid karyotype with 7% polyploidy - 47(47-48)<2n>X, -X, +8, +16, del(7)(p14), der(9)del(9)(q13q34)t(9;22)(q34;q11), der(22)t(9;22)(q34;q11) - carries t(9;22) effecting BCR-ABL1 rearrangement - resembles published karyotype

Disease

Adult B Acute Lymphoblastic Leukemia

Quality Control

Mycoplasma: negative in microbiological culture, PCR assays
Immunology: CD2 -, CD3 -, CD4 -, CD7 -, CD10 +, CD13 +, CD19 +, CD20 +, CD34 +, CD37 +, CD38 +, cyCD79a +, CD80 -, CD138 -, HLA-DR +, sm/cyIgG -, sm/cyIgM -, sm/cykappa -, sm/cylambda -
Viruses:

Storage and Shipping

Frozen with 70% medium, 20% FBS, 10% DMSO at about 6 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen

Synonyms

TOM1

Citation Guidance

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

The TOM-1 cell line is a human B-cell precursor leukemia line established in 1983 from the bone marrow of a 54-year-old female patient with refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is characterized by a hyperdiploid karyotype with a t(9;22) translocation, resulting in the expression of the p190 BCR-ABL1 fusion protein (e1a2 junction). Morphologically, TOM-1 cells are small, round lymphocytes that grow in suspension, either singly or in loose clusters, though some may show loose adherence. They are positive for HLA-DR, CD10, CD19, CD20, CD34, and terminal deoxynucleotidyl transferase (TdT), but negative for surface and cytoplasmic immunoglobulins, confirming their early pre-B cell stage. Culturally, they are maintained in a nutrient-rich basal medium supplemented with serum under standard conditions (37°C, 5% CO₂). The line has a doubling time of approximately 50-70 hours and is sub-cultured upon reaching appropriate density.

TOM-1 is a valuable model for studying Ph+ ALL pathogenesis, BCR-ABL1 signaling, tyrosine kinase inhibitor sensitivity, and mechanisms of leukemic stem cell differentiation and drug resistance.

Biological Effects of LIMKi in BCR::ABL+ Cell Lines

Despite advances with TKIs, Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL) remains a high-risk malignancy, necessitating less toxic strategies, particularly for elderly patients. Berrou et al. evaluated targeting LIMK1/2-key downstream effectors of BCR::ABL that regulate apoptosis via cofilin phosphorylation.

As BCR::ABL activates the ROCK-LIMK axis, they investigated the efficacy of the LIMK inhibitor CEL_Amide in Ph+ B-ALL cell lines (TOM-1, BV-173). CEL_Amide significantly inhibited cell viability with IC50s of 580 nM (TOM-1) and 1090 nM (BV-173) (Fig. 1A). Treatment induced dose-dependent apoptosis, reaching 45% (TOM-1) and 50% (BV-173) at 48 h (Fig. 1B), and caused G1/S cell cycle arrest (Fig. 1C). These findings suggest that LIMK inhibition disrupts critical survival pathways in Ph+ B-ALL.

In vitro effect of LIMKi on viability, apoptosis, and cell cycle in BCR::ABL1+ ALL cell lines — Fig. 1. *In vitro* effect of LIMKi on viability, apoptosis, and cell cycle in *BCR::ABL1*+ ALL cell lines (Berrou J, Dupont M, *et al*., 2022).

Ask a Question

Write your own review

You May Also Need

CM-1448Y

SuperCult® RPMI 1640 Medium

INQUIRY

CS-001Y

PremSera® FBS

INQUIRY

WILL-1

Description: Established in 2007 from the bone marrow mononuclear cells of an 82-year-old Japanese man with diffuse large B-cell lymphoma in the leukemic phase

Cat#: CSC-C0633 INQUIRY

View Product

TALL-1

Description: Established from the bone marrow of a 28-year-old man who developed the terminal leukemic phase of lymphosarcoma in 1976

Cat#: CSC-C0530 INQUIRY

View Product

KG-1

Description: This cell line was derived from the bone marrow aspirate of a 59 year old male with erythroleukemia that became acute myelogenous leukaemia.The cells form colonies in soft-agar in the presence of ...

Cat#: CSC-C8220L INQUIRY

View Product

L-82

Description: Established from the pleural effusion of a 24-year-old woman with recurrent anaplastic large cell lymphoma (ALCL); cells were described to clonally derive from T-lineage lymphoid cells and to be ...

Cat#: CSC-C0600 INQUIRY

View Product

SUP-HD1

Description: Established from a 37-year-old man at second (refractory/terminal) relapse of Hodgkin lymphoma (nodular sclerosing -> lymphocyte depleted/stage IIISA -> stage IV) after both combined chemo- and ...

Cat#: CSC-C0579 INQUIRY

View Product

MHH-CALL-4

Description: Established from the peripheral blood of a 10-year-old Caucasian boy with acute lymphoblastic leukemia (pre B-ALL) at diagnosis in 1993

Cat#: CSC-C0396 INQUIRY

View Product

For research use only. Not for any other purpose.